Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Prostate Cancer, Version 5.2026 Featured Updates to the NCCN Guidelines

Prostate Cancer, Version 5.2026 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D'Amico, A., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Ippolito, J. E., Karnes, R., Kishan, A. U., Kuettel, M. R., Lang, J. M., Lee, D., Lotan, T., McDonald, A., Morgan, T. M., Pessoa, R., Rais-Bahrami, S., Roach Iii, M., Robin, T., Rosenfeld, S., Scarpato, K. R., Seibert, T., Shabsigh, A., Szmulewitz, R., Teply, B. A., Tward, J., Valicenti, R., VanderWeele, D., Wong, J., Kovach, E., Freedman-Cass, D. 2026; 24 (5): 140-149

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.

View details for DOI 10.6004/jnccn.2026.0023

View details for Web of Science ID 001778070100007

View details for PubMedID 42134408